New Research Shows Promise and Limitations of Physicians Working with GPT-4 for Decision Making
The study was conducted with 50 U.S.-licensed physicians in family medicine, internal medicine and emergency medicine.
The study was conducted with 50 U.S.-licensed physicians in family medicine, internal medicine and emergency medicine.
The computational tool is called PIONEER (Protein-protein InteractiOn iNtErfacE pRediction). Researchers demonstrated PIONEER's utility by identifying potential drug targets for dozens of cancers and other complex diseases in a recently published Nature Biotechnology article.
In a test whose results were published today, the video system recognized and identified, with high proficiency, which medications were being drawn in busy clinical settings.
The study results, published in the October 21, 2024 online edition of the New England Journal of Medicine (NEJM) AI,
The design, validation and comparative assessment of this computational suite, NeoDisc, are detailed in the current issue of Nature Biotechnology in a publication led by Florian Huber and Michal Bassani-Sternberg of the Lausanne Branch of the Ludwig Institute for Cancer Research.
The researchers said that, while the model could be prompted in ways that make its responses more accurate, it's still no match for the clinical judgment of a human doctor.